Excess PTP1B activity is associated with important pathologies such as type II diabetes, obesity [54,55] and tumorigenesis [53], which has driven the search for PTP1B inhibitors [56]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.